Myeloproliferative Syndrome Clinical Trials
2 recruiting trials for Myeloproliferative Syndrome. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Myeloproliferative Syndrome clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 is the largest group at 50% (1 studies); the largest phase groups are Phase 1: 1, Phase 2: 1.
Research is led by University of Wisconsin, Madison (1), University of Liege (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is TCRαβ+/CD19+ depleted Haploidentical HSCT (procedure, 1 trial), followed by Zoledronate, Thymoglobulin.
Track Myeloproliferative Syndrome trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid...
This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with...
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG...
The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Myeloproliferative Syndrome, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Myeloproliferative Syndrome, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Myeloproliferative Syndrome, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.